» Articles » PMID: 26863873

Cancer Clinical Trial Enrollment of Diverse and Underserved Patients Within an Urban Safety Net Hospital

Overview
Specialties Critical Care
Oncology
Date 2016 Feb 12
PMID 26863873
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Enrollment rates onto cancer clinical trials are low and reflect a small subset of the population of which even fewer participants come from populations of racial or ethnic diversity or low socioeconomic status. There is a need to increase enrollment onto cancer clinical trials with a focus on recruitment of a diverse, underrepresented patient population.

Objective: To use the electronic medical record (EMR) to understand the eligibility and enrollment rates for all available cancer trials in the ambulatory care setting at an urban safety net hospital to identify specific strategies for enhanced accrual onto cancer clinical trials of diverse and underserved patients.

Methods: A clinical trial screening note was created for the EMR by the clinical trials office at an urban safety net hospital. 847 cancer clinical trial screening notes were extracted from the EMR between January 1, 2010 and December 31, 2010. During that time, 99 cancer trials were registered for accrual, including clinical treatment, survey, data repository, imaging, and symptom management trials. Data on eligibility, enrollment status, and relationship to sociodemographic status were compared.

Limitations: This is a single-institution and retrospective study.

Conclusions: The findings demonstrate that a formal process of tracking cancer clinical trial screens using an EMR can document baseline rates of institution-specific accrual patterns and identify targeted strategies for increasing cancer clinical trial enrollment among a vulnerable patient population. Offering nontreatment trials may be an important and strategic method of engaging this vulnerable population in clinical research.

Citing Articles

The role of social, economic, and medical marginalization in cancer clinical trial participation inequities: A systematic review.

Hanvey G, Johnson H, Cartagena G, Dede D, Krieger J, Ross K J Clin Transl Sci. 2025; 9(1):e25.

PMID: 40052046 PMC: 11883616. DOI: 10.1017/cts.2024.677.


Novel semi-automated algorithm for high-throughput quantification of adipocyte size in breast adipose tissue, with applications for breast cancer microenvironment.

Lombardi F, Jafari N, Bertrand K, Oshry L, Cassidy M, Ko N Adipocyte. 2020; 9(1):313-325.

PMID: 32633194 PMC: 7469507. DOI: 10.1080/21623945.2020.1787582.


Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey.

Cook E, Yeager K, Cecchini R, Boparai J, Brown C, Duncan M Contemp Clin Trials Commun. 2018; 10:100-104.

PMID: 30023443 PMC: 6046466. DOI: 10.1016/j.conctc.2018.03.003.


Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

Pang H, Wang X, Stinchcombe T, Wong M, Cheng P, Ganti A J Clin Oncol. 2016; 34(33):3992-3999.

PMID: 27646951 PMC: 5477832. DOI: 10.1200/JCO.2016.67.7088.


White-Black Differences in Cancer Incidence, Stage at Diagnosis, and Survival among Adults Aged 85 Years and Older in the United States.

Krok-Schoen J, Fisher J, Baltic R, Paskett E Cancer Epidemiol Biomarkers Prev. 2016; 25(11):1517-1523.

PMID: 27528599 PMC: 5568687. DOI: 10.1158/1055-9965.EPI-16-0354.